Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

1. Bupropion

Bupropion Top results for bupropion - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for bupropion The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients

Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients Published 7 May 2018 Statement of Advice: naltrexone hydrochloride / bupropion hydrochloride 8mg / 90mg prolonged-release tablets (Mysimba ® ) SMC2086 Orexigen Therapeutics Ireland Limited 6 April 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation naltrexone / bupropion (Mysimba ® ) is not recommended

Scottish Medicines Consortium2018

3. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial 29630702 2018 04 09 2168-6114 2018 Apr 09 JAMA internal medicine JAMA Intern Med Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. 10.1001/jamainternmed.2018.0397 Quitting smoking is enhanced by the use of pharmacotherapies, but concerns have been raised regarding the cardiovascular safety of such medications. To compare (...) of follow up and agreed to be followed up for an additional 28 weeks (n = 4595), were included. Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering. The primary end point was the time to development of a major adverse cardiovascular event (MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) during treatment; secondary end points were the occurrence of MACE and other pertinent cardiovascular

EvidenceUpdates2018

5. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD (...) , not all adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD. OBJECTIVES: To assess the effects and safety of bupropion for the treatment of adults

Cochrane2017

6. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease 28473506 2017 05 05 2017 05 05 1468-3296 2017 May 04 Thorax Thorax Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. thoraxjnl-2017-210067 10.1136/thoraxjnl-2017-210067 Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers (...) with COPD. To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD. In a retrospective cohort study, we used data from 14 350 patients with COPD included in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350

EvidenceUpdates2017

7. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. 26954408 2016 03 09 2016 03 14 2016 10 17 1538-3598 315 10 2016 Mar 08 JAMA JAMA Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. 990-1004 10.1001/jama.2016.1558 Few cardiovascular outcomes trials have been conducted (...) for obesity treatments. Withdrawal of 2 marketed drugs has resulted in controversy about the cardiovascular safety of obesity agents. To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients. Randomized, multicenter, placebo-controlled, double-blind noninferiority trial enrolling 8910 overweight or obese

JAMA2016

8. Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness

Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness (...) Published on: March 8, 2016 Project Number: RC0747-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of nicotine replacement therapy versus bupropion or varenicline in the general population of tobacco users? What is the comparative clinical effectiveness of nicotine replacement therapy, bupropion or varenicline versus placebo in the general population of tobacco users? Key Message Ten relevant

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

9. Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss

Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Prescrire IN ENGLISH - Spotlight ''Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss'', 1 October 2015 {1} {1} {1} | | > > > Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss FEATURED REVIEW On average, obese or overweight patients taking naltrexone + bupropion lose only a few kilograms. In contrast, its neuropsychiatric adverse effects are numerous and potentially severe. There is also a risk of hypertension, cardiac arrhythmia and gastrointestinal adverse effects. Full review (4 pages) available for download by subscribers. Abstract Weight loss and its long-term maintenance are mainly based on dietary

Prescrire2015

10. Does any antidepressant besides bupropion help smokers quit?

Does any antidepressant besides bupropion help smokers quit? Does any antidepressant besides bupropion help smokers quit? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does any antidepressant besides bupropion help smokers quit? View/ Open Date 2014-11 Format Metadata Abstract Q: Does any antidepressant besides (...) bupropion help smokers quite? Evidence-based answer: Yes, nortriptyline approximately doubles smoking cessation rates, an effect comparable to bupropion. Adding nortriptyline to nicotine replacement therapy (NRT) doesn’t improve rates further (strength of recommendation [SOR]: A, systematic review of randomized controlled trials [RCTs]). Selective serotonin reuptake inhibitors (SSRIs; fluoxetine, paroxetine, sertraline, citalopram), venlafaxine, mono-amine oxidase inhibitors (MAOIs; moclobemide

Clinical Inquiries2015

11. Naltrexone and Bupropion Combination: A New Promising Therapy for Long Term Weight Loss

Naltrexone and Bupropion Combination: A New Promising Therapy for Long Term Weight Loss "Naltrexone and Bupropion Combination: A New Promising Therapy for Long" by Sam Q. Nguyen < > > > > > Title Author Date of Award Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Being overweight or obese is a growing health concern not just in the United States, but worldwide (...) dependence, and bupropion is commonly used for depression. Separately, these two medications have been shown to reduce weight weakly; this review aims to evaluate the benefits of naltrexone and bupropion used in combination for weight loss. Method: An exhaustive literature search using the search engines Medline-OVID, CINAHL, and Web of Science combining keywords naltrexone, bupropion, and weight loss was conducted. Eligible criteria include research with naltrexone and bupropion combination therapy

Pacific University EBM Capstone Project2015

13. Bupropion confirmed not to cause weight gain in a real-world clinical population

Bupropion confirmed not to cause weight gain in a real-world clinical population Bupropion confirmed not to cause weight gain in a real-world clinical population | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Bupropion confirmed not to cause weight gain in a real-world clinical population Article Text Pharmacological interventions Bupropion confirmed not to cause weight gain in a real-world clinical population Scott B Patten Statistics from Altmetric.com No Altmetric data available for this article. COMMENTARY ON: Blumenthal SR Castro VM

Evidence-Based Mental Health2015

14. In women with SSRI-induced sexual dysfunction, does addition of bupropion to current therapy improve sexual function?

In women with SSRI-induced sexual dysfunction, does addition of bupropion to current therapy improve sexual function? In women with SSRI-induced sexual dysfunction, does addition of bupropion to current therapy improve sexual function? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics In women with SSRI-induced sexual (...) dysfunction, does addition of bupropion to current therapy improve sexual function? View/ Open Date 2014-06 Format Metadata Abstract In women with SSRI-induced sexual dysfunction, a trial of bupropion sustained-release (SR) 150 mg twice daily for at least 12 weeks can improve sexual desire (SOR: A, RCTs with consistent results). Bupropion add-on treatment may also improve other aspects of sexual function, such as arousal, lubrication, orgasm, and satisfaction (SOR: B, inconsistent results from RCTs). URI

Evidence Based Practice 2014

15. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und (...) mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion

Health Technology Assessment (HTA) Database.2014

16. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.

Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. IMPORTANCE: Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence. OBJECTIVE: To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers. DESIGN, SETTING, AND PARTICIPANTS: Randomized, blinded, placebo-controlled multicenter clinical (...) trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites. Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study. INTERVENTIONS: Twelve weeks of varenicline and bupropion SR or varenicline and placebo. MAIN OUTCOMES AND MEASURES: Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date

JAMA2014

17. Bupropion

Bupropion USE OF BUPROPION IN PREGNANCY 0344 892 0909 USE OF BUPROPION IN PREGNANCY (Date of issue: August 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Bupropion is a noradrenaline and dopamine selective reuptake inhibitor (...) licensed for use as a smoking cessation aid in the UK. In other countries bupropion is also licensed for use at a higher dose as an antidepressant. Much of the available pregnancy exposure data are collected from studies investigating its use as an antidepressant, which limits the conclusions we are able to provide concerning its use as a smoking cessation aid. There are several large population-based cohort studies which show no association between maternal bupropion use and an increase in overall

UK Teratology Information Service2014

18. Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets

Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets Company: Orexigen Therapeutics, Inc. Application No.: 200063 Approval Date: 9/10/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796

FDA - Drug Approval Package2014

19. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.

Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. 24399554 2014 01 08 2014 01 13 2016 12 15 1538-3598 311 2 2014 Jan 08 JAMA JAMA Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. 155-63 10.1001/jama.2013.283185 Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence. To determine efficacy and safety of varenicline and bupropion (...) sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers. Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites. Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study. Twelve weeks of varenicline and bupropion SR or varenicline and placebo

JAMA2014 Full Text: Link to full Text with Trip Pro

20. Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes 24144653 2013 11 22 2014 12 11 2016 12 15 1935-5548 36 12 2013 Dec Diabetes care Diabetes Care Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. 4022-9 10.2337/dc13-0234 To assess (...) the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro